Translate Bio Overview
Share Price
$21.02
(As of Tuesday Closing)
Translate Bio General Information
Description
Translate Bio Inc is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, for the treatment of cystic fibrosis (CF) and MRT5201, for the treatment of ornithine transcarbamylase (OTC) deficiency.
Translate Bio Timeline
Want to dig into this profile?
We’ll help you find what you need
Learn more
Translate Bio Stock Performance
(As of Tuesday closing)
| Stock Price |
Previous Close |
52 wk Range |
Market Cap |
Shares |
Average Volume |
EPS |
| $21.02 |
$20.44 |
$6.80 - $21.95 |
$1.32B |
62.9M |
607K |
-$1.73 |
Translate Bio Financials Summary
In Thousands,
USD
|
TTM
31-Mar-2020
|
FY 2019
31-Dec-2019
|
FY 2018
31-Dec-2018
|
FY 2017
31-Dec-2017
|
| EV |
422,430 |
291,136 |
177,466 |
|
| Revenue |
10,984 |
7,804 |
1,420 |
0 |
| EBITDA |
(91,318) |
(111,057) |
(101,442) |
(77,620) |
| Net Income |
(94,377) |
(113,293) |
(97,395) |
(66,443) |
| Total Assets |
305,242 |
336,201 |
287,651 |
198,547 |
| Total Debt |
12,504 |
12,614 |
0 |
0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Translate Bio Valuation & Funding
| Deal Type |
Date |
Amount |
Valuation/
EBITDA |
Post-Val |
Status |
Debt |
This information is available in the PitchBook Platform. To explore Translate Bio‘s full profile, request access.
Request a free trial
Translate Bio Cap Table
| Stock |
# of Shares
Authorized |
Par Value |
Dividend Rate (%) |
Original
Issue Price |
Liquidation |
Liquidation
Pref. Multiple |
Conversion
Price |
% Owned |
This information is available in the PitchBook Platform. To explore Translate Bio‘s full profile, request access.
Request a free trial
Translate Bio Competitors (25)
| Company Name |
Financing Status |
Location |
Employees |
Total Raised |
Last Financing Date/Type |
Last Financing
Amount |
| OncoResponse |
Venture Capital-Backed |
Seattle, WA |
00 |
000.00 |
00000000000 |
000.00 |
| 00000 000000000 |
Formerly VC-backed |
South San Francisco, CA |
000 |
00000 |
000000 - 000 |
00000 |
| 00000000000 |
Angel-Backed |
Culver City, CA |
|
00000 |
000000000000 |
00000 |
| 000000000 00000000 |
Venture Capital-Backed |
Rockville, MD |
|
000.00 |
0000000000 0 |
000.00 |
| 000000 00000000000 |
Formerly VC-backed |
Burlingame, CA |
00 |
00000 |
00000000 |
00000 |
Translate Bio Executive Team (17)
| Name |
Title |
Board Seat |
Contact Info |
| Ronald Renaud Jr. |
Chief Executive Officer & Board Member |
|
|
| John Schroer |
Chief Financial Officer, Finance & Chief Accounting Officer, Accounting |
|
|
| Paul Burgess JD |
Chief Operating Officer, Operations & Secretary, Administration |
|
|
| Richard Wooster Ph.D |
Chief Scientific Officer |
|
|
| Michael Heartlein Ph.D |
Executive Vice President & Founder |
|
|
9 Former Executives
Translate Bio Board Members (16)
To view Translate Bio‘s full board member team, request access >>
| Name |
Representing |
Role |
Since |
| Ankit Mahadevia MD |
Atlas Venture |
Board Member |
000 0000
|
| Daniel Lynch |
Self |
Chairman & Board Member |
000 0000
|
| George Demetri MD |
Self |
Board Member |
000 0000
|
| Iain Dukes Ph.D |
Self |
Board Member |
000 0000
|
| Jean-Francois Formela MD |
Self |
Board Member |
000 0000
|
8 Former Board Members